Prostate Cancer Screening — HopeScan Initiative

Prostate Cancer

Prostate cancer is one of the most common cancers affecting men in sub-Saharan West Africa, with some of the highest mortality rates in the world.

Men of African ancestry face a greater risk of developing aggressive forms of prostate cancer, yet access to screening, early diagnosis, and treatment remains limited across many communities.

Between 2020 and 2050, prostate cancer cases in the region are projected to rise dramatically, placing increasing strain on already limited healthcare resources and highlighting the urgent need for expanded screening and care access.

The Growing Burden in West Africa

In 2020, Africa recorded an estimated 77,000–80,000 new prostate cancer cases and 47,000–50,000 deaths, with most occurring in sub Saharan countries.
Mortality rates are significantly higher than in high income regions due to late stage diagnosis, limited PSA testing, and constrained access to urologists, biopsy services, radiotherapy, and systemic treatments.
By 2040, projections indicate that prostate cancer incidence in Africa could increase by 80–100%, reaching 140,000–160,000 new cases annually.
By 2050, demographic trends suggest that many sub Saharan countries may experience more than a two fold increase in new cases compared with 2020.
Five year prevalence is rising steadily, meaning more men living with prostate cancer, often without adequate long term care or follow up.

Key Challenges

Late presentation: Many men seek care only when symptoms become severe, leading to advanced stage diagnosis.
Limited screening access: PSA testing and DRE are not routinely available in many communities.
Diagnostic delays: Long waits for biopsy, pathology, and imaging increase the risk of disease progression.
Treatment barriers: Shortages of specialists and high out of pocket costs limit access to surgery, radiotherapy, and hormone therapy.
Stigma and low awareness: Men often normalize urinary symptoms or avoid discussing prostate health.

Expanding Access to Prostate Cancer Screening and Early Detection

HopeScan advances prostate cancer early detection through integrated PSA testing programs, strengthened diagnostic pathways, and community-based outreach. By combining patient navigation, provider training, and education initiatives, we reduce barriers to care, improve timely diagnosis, and expand equitable access to life-saving treatment for underserved men.